Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections

References

• Price WH. The isolation of a new virus associated with respiratory clinical disease in humans. Proc Natl Acad Sci USA. 1956;42(12):892–896. doi:10.1073/pnas.42.12.892
   Web of Science ®Google Scholar
• Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310(6989):1225–1229. doi:10.1136/bmj.310.6989.1225
   PubMed Web of Science ®Google Scholar
• Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618–1623. doi:10.1164/ajrccm.164.9.2105011
   PubMed Web of Science ®Google Scholar
• Aponte FE, Taboada B, Espinoza MA, et al. Rhinovirus is an important pathogen in upper and lower respiratory tract infections in Mexican children. Virol J. 2015;12:31. doi:10.1186/s12985-015-0262-z
   Web of Science ®Google Scholar
• Redlberger-Fritz M, Kundi M, Aberle SW, Puchhammer-Stöckl E. Significant impact of nationwide SARS-CoV-2 lockdown measures on the circulation of other respiratory virus infections in Austria. J Clin Virol. 2021;137:104795. doi:10.1016/j.jcv.2021.104795
   PubMed Web of Science ®Google Scholar
• Weston S, Frieman MB. Respiratory Viruses. Reference Module in Biomedical Sciences. Elsevier; 2018.
   Google Scholar
• Cafferkey J, Coultas JA, Mallia P. Human rhinovirus infection and COPD: role in exacerbations and potential for therapeutic targets. Expert Rev Respir Med. 2020;14(8):777–789. doi:10.1080/17476348.2020.1764354
   PubMed Web of Science ®Google Scholar
• Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–162.
   PubMed Web of Science ®Google Scholar
• McIntyre CL, Knowles NJ, Simmonds P. Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types. J Gen Virol. 2013;94(Pt 8):1791–1806. doi:10.1099/vir.0.053686-0
   PubMed Web of Science ®Google Scholar
• Lamson D, Renwick N, Kapoor V, et al. MassTag polymerase-chain-reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza-like illness in New York State during 2004–2005. J Infect Dis. 2006;194(10):1398–1402. doi:10.1086/508551
   Web of Science ®Google Scholar
• Lau SKP, Yip CCY, Woo PCY, Yuen KY. Human rhinovirus C: a newly discovered human rhinovirus species. Emerg Health Threats J. 2010;4(3):e2.
   Google Scholar
• Palmenberg AC, Rathe JA, Liggett SB. Analysis of the complete genome sequences of human rhinovirus. J Allergy Clin Immunol. 2010;125(6):1190–1199. doi:10.1016/j.jaci.2010.04.010
   PubMed Web of Science ®Google Scholar
• Spickler C, Lippens J, Laberge M-K, et al. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob Agents Chemother. 2013;57(7):3358–3368. doi:10.1128/AAC.00303-13
   PubMed Web of Science ®Google Scholar
• Ambros V, Baltimore D. Protein is linked to the 5’ end of poliovirus RNA by a phosphodiester linkage to tyrosine. J Biol Chem. 1978;253(15):5263–5266. doi:10.1016/S0021-9258(17)30361-7
   PubMed Web of Science ®Google Scholar
• Sun D, Chen S, Cheng A, Wang M. Roles of the picornaviral 3C proteinase in the viral life cycle and host cells. Viruses. 2016;8(3):82. doi:10.3390/v8030082
   PubMed Web of Science ®Google Scholar
• Appleby TC, Luecke H, Shim JH, et al. Crystal structure of complete rhinovirus RNA polymerase suggests front loading of protein primer. J Virol. 2005;79(1):277–288. doi:10.1128/JVI.79.1.277-288.2005
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Condra JH, Mizutani S, Callahan PL, Davies ME, Murcko MA. Evidence for the direct involvement of the rhinovirus canyon in receptor binding. Proc Natl Acad Sci USA. 1988;85(15):5449–5453. doi:10.1073/pnas.85.15.5449
   PubMed Web of Science ®Google Scholar
• Bella J, Rossmann MG. ICAM-1 receptors and cold viruses. Pharm Acta Helv. 2000;74(2–3):291–297. doi:10.1016/S0031-6865(99)00056-4
   Google Scholar
• Liu Y, Hill MG, Klose T, et al. Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma. Proc Natl Acad Sci USA. 2016;113(32):8997–9002. doi:10.1073/pnas.1606595113
   Web of Science ®Google Scholar
• Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci USA. 1994;91(5):1839–1842. doi:10.1073/pnas.91.5.1839
   PubMed Web of Science ®Google Scholar
• Bochkov YA, Palmenberg AC, Lee WM, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627–632. doi:10.1038/nm.2358
   PubMed Web of Science ®Google Scholar
• Everman JL, Sajuthi S, Saef B, et al. Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations. J Allergy Clin Immunol. 2019;144(4):962–971. doi:10.1016/j.jaci.2019.01.052
   PubMed Web of Science ®Google Scholar
• Laza-Stanca V, Stanciu LA, Message SD, Edwards MR, Gern JE, Johnston SL. Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production. J Virol. 2006;80(16):8248–8258. doi:10.1128/JVI.00162-06
   PubMed Web of Science ®Google Scholar
• Slater L, Bartlett NW, Haas JJ, et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog. 2010;6(11):e1001178. doi:10.1371/journal.ppat.1001178
   PubMed Web of Science ®Google Scholar
• Fensterl V, Chattopadhyay S, Sen GC. No love lost between viruses and interferons. Annu Rev Virol. 2015;2(1):549–572. doi:10.1146/annurev-virology-100114-055249
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Turner RB, Braciale T, Heymann PW, Borish L. Pathogenesis of rhinovirus infection. Curr Opin Virol. 2012;2(3):287–293. doi:10.1016/j.coviro.2012.03.008
   PubMed Web of Science ®Google Scholar
• Kaul P, Biagioli MC, Singh I, Turner RB. Rhinovirus-induced oxidative stress and interleukin-8 elaboration involves p47-phox but is independent of attachment to intercellular adhesion molecule-1 and viral replication. J Infect Dis. 2000;181(6):1885–1890. doi:10.1086/315504
   PubMed Web of Science ®Google Scholar
• Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res. 2006;7(1):116. doi:10.1186/1465-9921-7-116
   Web of Science ®Google Scholar
• Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183(6):734–742. doi:10.1164/rccm.201006-0833OC
   PubMed Web of Science ®Google Scholar
• Footitt J, Mallia P, Durham AL, et al. Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD. Chest. 2016;149(1):62–73. doi:10.1378/chest.14-2637
   PubMed Web of Science ®Google Scholar
• Hilzendeger C, da Silva J, Henket M, et al. Reduced sputum expression of interferon-stimulated genes in severe COPD. Int J Chron Obstruct Pulmon Dis. 2016;Volume 11(11):1485–1494. doi:10.2147/COPD.S105948
   Web of Science ®Google Scholar
• García-Valero J, Olloquequi J, Montes JF, et al. Deficient pulmonary IFN-β expression in COPD patients. PLoS One. 2019;14(6):e0217803. doi:10.1371/journal.pone.0217803
   PubMed Web of Science ®Google Scholar
• Baines KJ, Hsu ACY, Tooze M, Gunawardhana LP, Gibson PG, Wark PAB. Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD. Respir Res. 2013;14:15. doi:10.1186/1465-9921-14-15
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Loo SL, Calderazzo M, et al. Antiviral immunity is impaired in COPD patients with frequent exacerbations. Am J Physiol Lung Cell Mol Physiol. 2019;317(6):L893–L903. doi:10.1152/ajplung.00253.2019
   PubMed Web of Science ®Google Scholar
• Wark PAB, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–947. doi:10.1084/jem.20041901
   PubMed Web of Science ®Google Scholar
• Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026. doi:10.1038/nm1462
   PubMed Web of Science ®Google Scholar
• Edwards MR, Regamey N, Vareille M, et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 2013;6(4):797–806. doi:10.1038/mi.2012.118
   PubMed Web of Science ®Google Scholar
• Miller EK, Hernandez JZ, Wimmenauer V, et al. A mechanistic role for type III IFN-λ1 in asthma exacerbations mediated by human rhinoviruses. Am J Respir Crit Care Med. 2012;185(5):508–516. doi:10.1164/rccm.201108-1462OC
   PubMed Web of Science ®Google Scholar
• Hansel TT, Tunstall T, Trujillo-Torralbo M-B, et al. A comprehensive evaluation of nasal and bronchial cytokines and chemokines following experimental rhinovirus infection in allergic asthma: increased interferons (IFN-γ and IFN-λ) and type 2 inflammation (IL-5 and IL-13). EBioMedicine. 2017;19:128–138. doi:10.1016/j.ebiom.2017.03.033
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Shaker M, McMeen V, et al. Comparison of viral load in individuals with and without asthma during infections with rhinovirus. Am J Respir Crit Care Med. 2014;189(5):532–539. doi:10.1164/rccm.201310-1767OC
   Web of Science ®Google Scholar
• Farne HA, Johnston SL. Immune mechanisms of respiratory viral infections in asthma. Curr Opin Immunol. 2017;48:31–37. doi:10.1016/j.coi.2017.07.017
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Makrinioti H, Rana BMJ, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014;190(12):1373–1382. doi:10.1164/rccm.201406-1039OC
   PubMed Web of Science ®Google Scholar
• Tyrrell DA. A view from the common cold unit. Antiviral Res. 1992;18(2):105–125. doi:10.1016/0166-3542(92)90032-Z
   Web of Science ®Google Scholar
• Andrewes CH. The common cold. Br Med Bull. 1953;9(3):206–207. doi:10.1093/oxfordjournals.bmb.a074357
   Web of Science ®Google Scholar
• Rosenbaum JR, Sepkowitz KA. Infectious disease experimentation involving human volunteers. Clin Infect Dis. 2002;34(7):963–971. doi:10.1086/339328
   Web of Science ®Google Scholar
• Sperber SJ, Hunger SB, Schwartz B, Pestka S. Anti-rhinoviral activity of recombinant and hybrid species of interferon alpha. Antiviral Res. 1993;22(2–3):121–129. doi:10.1016/0166-3542(93)90090-6
   Web of Science ®Google Scholar
• Al-Nakib W, Higgins PG, Barrow I, Tyrrell DA, Lenox-Smith I, Ishitsuka H. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J Antimicrob Chemother. 1987;20(6):887–892. doi:10.1093/jac/20.6.887
   PubMed Web of Science ®Google Scholar
• al-Nakib W, Higgins PG, Barrow GI, et al. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother. 1989;33(4):522–525. doi:10.1128/AAC.33.4.522
   Web of Science ®Google Scholar
• Lemanske RF, Dick EC, Swenson CA, Vrtis RF, Busse WW. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest. 1989;83(1):1–10. doi:10.1172/JCI113843
   PubMed Web of Science ®Google Scholar
• Bardin PG, Fraenkel DJ, Sanderson G, et al. Amplified rhinovirus colds in atopic subjects. Clin Exp Allergy. 1994;24(5):457–464. doi:10.1111/j.1365-2222.1994.tb00934.x
   Web of Science ®Google Scholar
• de Gouw HW, Grünberg K, Schot R, Kroes AC, Dick EC, Sterk PJ. Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects. Eur Respir J. 1998;11(1):126–132. doi:10.1183/09031936.98.11010126
   Web of Science ®Google Scholar
• Heymann PW, Tae PM, Woodfolk JA, et al. Understanding the asthmatic response to an experimental rhinovirus infection: exploring the effects of blocking IgE. J Allergy Clin Immunol. 2020;146(3):545–554. doi:10.1016/j.jaci.2020.01.035
   Web of Science ®Google Scholar
• Zambrano JC, Carper HT, Rakes GP, et al. Experimental rhinovirus challenges in adults with mild asthma: response to infection in relation to IgE. J Allergy Clin Immunol. 2003;111(5):1008–1016. doi:10.1067/mai.2003.1396
   Web of Science ®Google Scholar
• Togo Y, Schwartz AR, Hornick RB. Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection. Antimicrob Agents Chemother. 1973;4(6):612–616. doi:10.1128/AAC.4.6.612
   Web of Science ®Google Scholar
• Turner RB, Riker DK, Gangemi JD. Ineffectiveness of echinacea for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother. 2000;44(6):1708–1709. doi:10.1128/AAC.44.6.1708-1709.2000
   PubMed Web of Science ®Google Scholar
• Gaffey MJ, Gwaltney JM, Sastre A, Dressler WE, Sorrentino JV, Hayden FG. Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. Am Rev Respir Dis. 1987;136(3):556–560. doi:10.1164/ajrccm/136.3.556
   PubMed Web of Science ®Google Scholar
• Winther B, Buchert D, Turner RB, Hendley JO, Tschaikin M. Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline. Am J Rhinol Allergy. 2010;24(5):374–377. doi:10.2500/ajra.2010.24.3491
   Web of Science ®Google Scholar
• Togo Y, Durr FE, Laurenzana DA. Clinical evaluation of prophylactic intranasal 1-phenyl-3-(4-phenyl-2-thiazolyl) guanidine (CL 88,277) medication against rhinovirus 44 challenge. Med Microbiol Immunol. 1977;163(1):37–44. doi:10.1007/BF02126707
   Web of Science ®Google Scholar
• Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bull N Y Acad Med. 1989;65(1):145–160.
   PubMedGoogle Scholar
• Higgins PG, al-Nakib W, Barrow GI, Tyrrell DA. Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers. J Interferon Res. 1988;8(5):591–596. doi:10.1089/jir.1988.8.591
   Google Scholar
• Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tyrrell DA. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J Antimicrob Chemother. 1987;20(6):893–901. doi:10.1093/jac/20.6.893
   Web of Science ®Google Scholar
• The Academy of Medical Sciences. Controlled human infection model studies: summary of a workshop held on 6 February 2018. The Academy of Medical Sciences [Internet]. 2018 [cited December 15, 2020]; Available from: https://acmedsci.ac.uk/file-download/55062331. Accessed June 4, 2021.
   Google Scholar
• Johnston SL. Experimental models of rhinovirus-induced exacerbations of asthma. Am J Respir Crit Care Med. 2003;168(10):1145–1146. doi:10.1164/rccm.2309004
   Web of Science ®Google Scholar
• Girkin J, Maltby S, Singanayagam A, Bartlett N, Mallia P. In vivo experimental models of infection and disease. In: Rhinovirus Infections. Elsevier; 2019:195–238.
   Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi:10.1016/S0140-6736(17)31281-3
   PubMed Web of Science ®Google Scholar
• Johnston SL, Szigeti M, Cross M, et al. Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial. JAMA Intern Med. 2016;176(11):1630–1637. doi:10.1001/jamainternmed.2016.5664
   PubMed Web of Science ®Google Scholar
• Djukanović R, Harrison T, Johnston SL, et al. The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014;190(2):145–154. doi:10.1164/rccm.201312-2235OC
   PubMed Web of Science ®Google Scholar
• Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 1992;36(4):727–732. doi:10.1128/AAC.36.4.727
   PubMed Web of Science ®Google Scholar
• Hayden FG, Hipskind GJ, Woerner DH, et al. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother. 1995;39(2):290–294. doi:10.1128/AAC.39.2.290
   PubMed Web of Science ®Google Scholar
• Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36(12):1523–1532. doi:10.1086/375069
   PubMed Web of Science ®Google Scholar
• Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016;131:61–65. doi:10.1016/j.antiviral.2016.04.003
   PubMed Web of Science ®Google Scholar
• Andersen DO, Murray BK, Robins RK, North JA. In vitro antiviral activity of ribavirin against picornaviruses. Antivir Chem Chemother. 1992;3(6):361–370. doi:10.1177/095632029200300606
   Web of Science ®Google Scholar
• Ruuskanen O, Waris M, Kainulainen L. Treatment of persistent rhinovirus infection with pegylated interferon α2a and ribavirin in patients with hypogammaglobulinemia. Clin Infect Dis. 2014;58(12):1784–1786. doi:10.1093/cid/ciu169
   Web of Science ®Google Scholar
• Turner RB, Wecker MT, Pohl G, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA. 1999;281(19):1797–1804. doi:10.1001/jama.281.19.1797
   PubMed Web of Science ®Google Scholar
• Vapendavir significantly improves upper respiratory symptoms of naturally acquired rhinovirus infection in asthmatic adults: results of a Phase 2 clinical trial | European Respiratory Society [Internet]. [ cited May 15, 2021]. Available from: https://erj.ersjournals.com/content/42/Suppl_57/1493. Accessed June 4, 2021.
   Google Scholar
• Jolliffe DA, Camargo CA, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021;9(5):276–292. doi:10.1016/S2213-8587(21)00051-6
   PubMed Web of Science ®Google Scholar
• Beaucourt S, Vignuzzi M. Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol. 2014;8:10–15. doi:10.1016/j.coviro.2014.04.011
   PubMed Web of Science ®Google Scholar
• Ledford RM, Patel NR, Demenczuk TM, et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol. 2004;78(7):3663–3674. doi:10.1128/JVI.78.7.3663-3674.2004
   Web of Science ®Google Scholar
• Basta HA, Ashraf S, Sgro JY, Bochkov YA, Gern JE, Palmenberg AC. Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance. Virology. 2014;448:82–90. doi:10.1016/j.virol.2013.10.004
   PubMed Web of Science ®Google Scholar
• Schwitzer G. How the media left the evidence out in the cold. BMJ. 2003;326(7403):1403–1404. doi:10.1136/bmj.326.7403.1403
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Effects of pleconaril nasal spray on common cold symptoms and asthma exacerbations following rhinovirus exposure (study P04295). ClinicalTrials.gov: ClinicalTrials.gov; 2015.
   Google Scholar
• Andries K, Dewindt B, Snoeks J, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992;36(1):100–107. doi:10.1128/AAC.36.1.100
   Web of Science ®Google Scholar
• Biota Pharmaceuticals. A phase 2 study of vapendavir in asthmatic adults with symptomatic human rhinovirus infection (SPIRITUS) [Internet]. ClinicalTrials.gov, editor. ClinicalTrials.gov: ClinicalTrials.gov; 2018 [cited February 28, 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT02367313. Accessed June 4, 2021.
   Google Scholar
• Wald J, Pasin M, Richter M, et al. Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site. Proc Natl Acad Sci USA. 2019;116(38):19109–19115. doi:10.1073/pnas.1904732116
   Web of Science ®Google Scholar
• Makarov VA, Braun H, Richter M, et al. Pyrazolopyrimidines: potent inhibitors targeting the capsid of rhino- and enteroviruses. Chem Med Chem. 2015;10(10):1629–1634. doi:10.1002/cmdc.201500304
   Web of Science ®Google Scholar
• Lacroix C, Laconi S, Angius F, et al. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virol J. 2015;12:106. doi:10.1186/s12985-015-0330-4
   PubMed Web of Science ®Google Scholar
• Dragovich PS, Prins TJ, Zhou R, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem. 1999;42(7):1213–1224. doi:10.1021/jm9805384
   Web of Science ®Google Scholar
• Patick AK, Binford SL, Brothers MA, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 1999;43(10):2444–2450. doi:10.1128/AAC.43.10.2444
   PubMed Web of Science ®Google Scholar
• Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res. 2000;47(3):215–220. doi:10.1016/S0166-3542(00)00106-6
   Web of Science ®Google Scholar
• Zalman LS, Brothers MA, Dragovich PS, et al. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother. 2000;44(5):1236–1241. doi:10.1128/AAC.44.5.1236-1241.2000
   Web of Science ®Google Scholar
• Hsyu PH, Yk P, Gersten M, Penning CA, Kerr BM. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother. 2002;46(2):392–397.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother. 2003;47(12):3907–3916. doi:10.1128/AAC.47.12.3907-3916.2003
   PubMed Web of Science ®Google Scholar
• Kawatkar SP, Gagnon M, Hoesch V, et al. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease. Bioorg Med Chem Lett. 2016;26(14):3248–3252. doi:10.1016/j.bmcl.2016.05.066
   Web of Science ®Google Scholar
• Sanders SP, Siekierski ES, Porter JD, Richards SM, Proud D. Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. J Virol. 1998;72(2):934–942. doi:10.1128/JVI.72.2.934-942.1998
   Web of Science ®Google Scholar
• Yang Z, Bochkov YA, Voelker DR, Foster MW, Que LG. Identification of a novel inhibitor of human rhinovirus replication and inflammation in airway epithelial cells. Am J Respir Cell Mol Biol. 2019;60(1):58–67. doi:10.1165/rcmb.2018-0058OC
   Web of Science ®Google Scholar
• Shim A, Song JH, Kwon BE, et al. Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model. Sci Rep. 2016;6:23110. doi:10.1038/srep23110
   PubMed Web of Science ®Google Scholar
• Sousa FH, Casanova V, Findlay F, et al. Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides. 2017;95:76–83. doi:10.1016/j.peptides.2017.07.013
   PubMed Web of Science ®Google Scholar
• Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol. 2008;181(10):7090–7099. doi:10.4049/jimmunol.181.10.7090
   PubMed Web of Science ®Google Scholar
• Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–1773. doi:10.1126/science.1123933
   PubMed Web of Science ®Google Scholar
• Telcian AG, Zdrenghea MT, Edwards MR, et al. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Antiviral Res. 2017;137:93–101. doi:10.1016/j.antiviral.2016.11.004
   PubMed Web of Science ®Google Scholar
• Schögler A, Muster RJ, Kieninger E, et al. Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37. Eur Respir J. 2016;47(2):520–530. doi:10.1183/13993003.00665-2015
   PubMed Web of Science ®Google Scholar
• Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240–4270. doi:10.3390/nu7064240
   PubMed Web of Science ®Google Scholar
• Jolliffe DA, Greiller CL, Mein CA, et al. Vitamin D receptor genotype influences risk of upper respiratory infection. Br J Nutr. 2018;120(8):891–900. doi:10.1017/S000711451800209X
   PubMed Web of Science ®Google Scholar
• Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. doi:10.1136/bmj.i6583
   PubMed Web of Science ®Google Scholar
• Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis. Health Technol Assess. 2019;23(2):1–44. doi:10.3310/hta23020
   PubMed Web of Science ®Google Scholar
• McCrae C, Olsson M, Gustafson P, et al. INEXAS: a phase 2 randomized trial of on-demand inhaled interferon beta-1a in severe asthmatics. Clin Exp Allergy. 2021;51(2):273–283. doi:10.1111/cea.13765
   PubMed Web of Science ®Google Scholar
• Watson A, Spalluto CM, McCrae C, et al. Dynamics of IFN-β responses during respiratory viral infection. Insights for therapeutic strategies. Am J Respir Crit Care Med. 2020;201(1):83–94. doi:10.1164/rccm.201901-0214OC
   PubMed Web of Science ®Google Scholar
• Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196–206. doi:10.1016/S2213-2600(20)30511-7
   PubMed Web of Science ®Google Scholar
• Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646–654. doi:10.1183/09031936.00095809
   PubMed Web of Science ®Google Scholar
• Porter JD, Watson J, Roberts LR, et al. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium. J Antimicrob Chemother. 2016;71(10):2767–2781. doi:10.1093/jac/dkw222
   PubMed Web of Science ®Google Scholar
• Menzel M, Akbarshahi H, Bjermer L, Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep. 2016;28(6):28698. doi:10.1038/srep28698
   Web of Science ®Google Scholar
• Mejdrová I, Chalupská D, Plačková P, et al. Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIβ (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology. J Med Chem. 2017;60(1):100–118. doi:10.1021/acs.jmedchem.6b01465
   Web of Science ®Google Scholar
• Greninger AL, Knudsen GM, Betegon M, Burlingame AL, Derisi JL. The 3A protein from multiple picornaviruses utilizes the golgi adaptor protein ACBD3 to recruit PI4KIIIβ. J Virol. 2012;86(7):3605–3616. doi:10.1128/JVI.06778-11
   Web of Science ®Google Scholar
• Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol. 2013;87(8):4252–4260. doi:10.1128/JVI.03546-12
   PubMed Web of Science ®Google Scholar
• Guedán A, Swieboda D, Charles M, et al. Investigation of the role of protein kinase D in human rhinovirus replication. J Virol. 2017;91(9). doi:10.1128/JVI.00217-17
   Web of Science ®Google Scholar
• Tóth B, Balla A, Ma H, Knight ZA, Shokat KM, Balla T. Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J Biol Chem. 2006;281(47):36369–36377. doi:10.1074/jbc.M604935200
   Web of Science ®Google Scholar
• Mousnier A, Bell AS, Swieboda DP, et al. Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nat Chem. 2018;10(6):599–606. doi:10.1038/s41557-018-0039-2
   PubMed Web of Science ®Google Scholar
• Carey BS, Barclay WS, Russell SM, Tyrrell DA. The specificity of antibodies induced by infection with rhinovirus type 2. J Med Virol. 1992;36(4):251–258. doi:10.1002/jmv.1890360404
   Web of Science ®Google Scholar
• Hastings GZ, Speller SA, Francis MJ. Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2. J Gen Virol. 1990;71(Pt 12)):3055–3059. doi:10.1099/0022-1317-71-12-3055
   Web of Science ®Google Scholar
• Hayden FG, Gwaltney JM, Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res. 1988;9(4):233–247. doi:10.1016/0166-3542(88)90055-1
   PubMed Web of Science ®Google Scholar
• Traub S, Nikonova A, Carruthers A, et al. An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLoS Pathog. 2013;9(8):e1003520. doi:10.1371/journal.ppat.1003520
   PubMed Web of Science ®Google Scholar
• Kim S-R, Song J-H, Ahn J-H, et al. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation. Antiviral Res. 2018;151:87–96. doi:10.1016/j.antiviral.2018.01.012
   PubMed Web of Science ®Google Scholar
• Kang H, Kim C, Kim D, et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral Res. 2015;124:1–10. doi:10.1016/j.antiviral.2015.10.011
   PubMed Web of Science ®Google Scholar
• Song JH, Kim SR, Heo EY, et al. Antiviral activity of gemcitabine against human rhinovirus in vitro and in vivo. Antiviral Res. 2017;145:6–13. doi:10.1016/j.antiviral.2017.07.003
   PubMed Web of Science ®Google Scholar
• Ganesan S, Faris AN, Comstock AT, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res. 2012;94(3):258–271. doi:10.1016/j.antiviral.2012.03.005
   PubMed Web of Science ®Google Scholar
• Farazuddin M, Mishra R, Jing Y, Srivastava V, Comstock AT, Sajjan US. Quercetin prevents rhinovirus-induced progression of lung disease in mice with COPD phenotype. PLoS One. 2018;13(7):e0199612. doi:10.1371/journal.pone.0199612
   PubMed Web of Science ®Google Scholar
• Han MK, Barreto TA, Martinez FJ, Comstock AT, Sajjan US. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir Res. 2020;7(1):e000392. doi:10.1136/bmjresp-2018-000392
   PubMed Web of Science ®Google Scholar
• Da Costa L, Scheers E, Coluccia A, et al. Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: a combined computational and experimental study. Eur J Med Chem. 2017;140:528–541. doi:10.1016/j.ejmech.2017.09.036
   Web of Science ®Google Scholar
• Nguyen A, Guedán A, Mousnier A, et al. Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets. J Lipid Res. 2018;59(9):1671–1684. doi:10.1194/jlr.M085910
   PubMed Web of Science ®Google Scholar
• Valbuena A, Rodríguez-Huete A, Mateu MG. Mechanical stiffening of human rhinovirus by cavity-filling antiviral drugs. Nanoscale. 2018;10(3):1440–1452. doi:10.1039/C7NR08704G
   Web of Science ®Google Scholar